European Interventional Cardiology Device Market Will Remain Stable Through 2022 at Over $1.2 Billion German and UK Markets Hold Most Growth Opportunities For Competitors, According to Millennium Research Group
TORONTO, Nov. 6, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the maturing European interventional cardiology (IC) device market will be supported by the uptake of complex procedures as well as adoption of innovative premium-priced products. Although percutaneous coronary interventions (PCIs) are well accepted in Europe, the applications for these treatments are continuing to expand, supporting total procedure volumes. For example, more physicians are now performing PCIs to treat chronic total occlusions (CTOs), especially given that companies such as ASAHI INTECC and Abbott Laboratories have designed accessory devices specifically for this purpose.
The market will also be supported by growing acceptance of some premium-priced devices. For example, physicians are very enthusiastic about the potential for bioresorbable vascular scaffolds (BVS), which the body gradually absorbs, leaving no permanent hardware. Similarly, the European Society of Cardiology has recently released favorable recommendations for using drug-coated balloons (DCBs) for in-stent restenosis, as well as for using fractional flow reserve (FFR) guidewires.
"While the use of these products is growing, the extent of adoption will be determined in the next few years," said MRG Analyst Leila Bautista. "Right now, the high cost of these products is prohibitive for many facilities in Europe, and reimbursement is not ideal. There is no significant competitive pricing pressure either because the technology is so new that not that many companies offer these products yet. Nonetheless, if reimbursement improves or these products become more affordable, they have considerable potential in Europe."
The German and United Kingdom markets will have the most favorable environment for competitors through 2022 because of higher acceptance of premium-priced devices and more favorable reimbursement, respectively. By contrast, Spain and Italy have been most severely affected by the economic situation in Europe, resulting in hindered PCI volumes and drastic price declines. France lies in between, with its IC device market remaining fairly stable.
Millennium Research Group's European Markets for Interventional Cardiology Devices 2014 report includes unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for coronary stents, percutaneous transluminal coronary angioplasty (PTCA) balloon catheters, accessory devices and intravascular imaging catheters and press guidewires in France, Germany, Italy, Spain and the United Kingdom.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
SOURCE Millennium Research Group